US 10,012,648 B2 · Plasma cytochrome C as a biomarker for mitochondrial toxicity during antiretroviral therapy

Abstract

The present invention relates to the discovery that measurement of the level of cytochrome c (Cyt-C) in the plasma can be used as a diagnostic signature to predict antiretroviral therapy (ART) toxicity in human immunodeficiency virus (HIV) infected patients. Thus, in various embodiments described herein, the methods of the invention relate to methods of diagnosing a HIV patient with ART toxicity, methods of predicting a patient's risk of having or developing toxicity for ART, methods of assessing if a patient will benefit from a change in the treatment strategies by adjusting the dosage and/or changing the medication or even terminating of ART, and methods of predicting antiretroviral drugs propensity for causing mitochondrial toxicity. Furthermore, the invention encompasses a diagnostic kit for carrying out the aforementioned methods.

Claims22

Dependent claims

A method for detecting antiretroviral drug toxicity in a subject having a viral infection, the method comprising:

i. detecting a level of Cytochrome c (Cyt-C) in a plasma sample from the subject;
ii. determining that the subject has antiretroviral drug toxicity when the level of Cyt-C in the plasma sample from the subject is at least 2 times more than the level of Cyt-C in a baseline reference;
and,
iii. administering a modified level of antiretroviral treatment to the subject having been determined to have antiretroviral drug toxicity.

1 more element

Dependencies are inferred from the claim text.

Plasma cytochrome C as a biomarker for mitochondrial toxicity during antiretroviral therapy

Life of this patent

Plasma cytochrome C as a biomarker for mitochondrial toxicity during antiretroviral therapy

Life of this patent

Abstract

Claims22